The Potential Role of Quercus Infectoria Gall Extract on Osteoblast Function and Bone Metabolism by Hapidin, Hermizi et al.
Open Journal of Endocrine and Metabolic Diseases, 2012, 2, 82-88 
doi:10.4236/ojemd.2012.24013 Published Online November 2012 (http://www.SciRP.org/journal/ojemd) 
The Potential Role of Quercus Infectoria Gall Extract on 
Osteoblast Function and Bone Metabolism 
Hermizi Hapidin1, Hasmah Abdullah1, Ima Nirwana Soelaiman2 
1Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia, Penang, Malaysia 
2Department of Pharmacology, UKM Medical Centre, Universiti Kebangsaan Malaysia, Bangi, Malaysia 
Email: hermizi@kck.usm.my 
 
Received September 7, 2012; revised October 8, 2012; accepted November 9, 2012 
ABSTRACT 
The galls of the Quercus infectoria (QI) tree are traditionally believed to have great medicinal value. Pharmacologically 
the galls are claimed to have various biological activities such as astringent effect, antidiabetic, antitremorine, local 
anaesthetic, antipyretic, anti-inflammatory, antibacterial, antiviral and many more. These pharmacological activities of 
gall extracts were reported to be due to its excellent antioxidant activity with phytochemicals constituents of phenolic 
and flavanoid compounds. The phenolic compounds or polyphenols can act on bone metabolism by modulating os-
teoblast proliferation, differentiation and mineralization, as well as osteoclastogenesis. In addition, elemental and phys-
ico-chemical analysis indicated the presence of important minerals in QI, such as calcium, magnesium, phosphorus, 
oxygen, potassium, aluminium, carbon, zinc, iron, manganese, nickel and silica. The current review will be focusing on 
the potential bone health benefits of the well-known traditional herbal medicine, QI or locally known as the “manja-
kani”. 
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1. Introduction 
Bone is a unique tissue providing support and mineral 
balance for the organism. It is formed during growth and 
is maintained during adult life by continuous renewal of 
the matrix, a process called bone remodeling. Bone 
remodeling is ensured by two cell types: osteoclasts, 
which resorb the calcified bone matrix, and osteoblasts, 
which are responsible for new bone matrix synthesis. 
During growth, bone formation exceeds bone resorption, 
resulting in bone expansion. In the young adult, bone 
resorption is balanced by bone formation, resulting in 
maintenance of bone mass. With aging and after the 
menopause, an imbalance in bone resorption relative to 
formation results in a negative bone balance at the tissue 
level. This may lead to osteoporosis, a common skeletal 
disease characterized by reduced bone mass, deteriora- 
tion of bone microarchitecture, and increased suscepti- 
bility to fractures [1,2]. 
Osteoporosis is now widely recognized as a public 
health problem since this disease is associated with 
significant mortality and morbidity as well as heavy 
medical expenses throughout the world. The current 
consensus is that approximately 1.66 million hip frac- 
tures occur each year worldwide. The incidence is set to 
increase 4-fold by the year 2050 because of the in- 
creasing numbers of older people and the age-adjusted 
incidence rates are many times higher in Western 
countries than in Asia and sub-Saharan African [3-5]. 
Although osteoporosis is widely regarded as a disease 
that affects women, it had also become a major problem 
for older men. Eastell et al. reported that 20% of sympto- 
matic spine fractures and 30% of hip fractures in coun- 
tries with high fracture rates occurred in men [6]. 
Osteoporosis is associated with huge personal and 
economic tolls. In Europe, the disability due to osteopo- 
rosis was greater than that caused by cancers (with the 
exception of lung cancer) and the resulting disability was 
comparable to or greater than the disability due to a variety 
of chronic non-communicable diseases, such as rheu- 
matoid arthritis, asthma and high blood pressure-related 
heart disease [7]. In Malaysia and Thailand, hip fracture 
rates of between 200 to 250 fractures per 100,000 were 
found [8]. Healthy urban midlife Malaysian women had a 
24% prevalence of osteoporosis and 51.6% of osteopenia, 
predominantly at the hip [9]. 
Various pharmacological agents for managing oste-
oporosis are available, for example hormone replacement 
therapy, bisphosphonates, calcium, calcitonin, androgens, 
parathormone and growth hormone. Conventional treat- 
ment results in varied adverse effects such as increased 
incidence of endometrial and breast cancer with hor- 
monal replacement therapy, pseudo-arthritis with fluo- 
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ride treatment, extra skeletal effects in cases treated with 
growth factors such as insulin like growth factor I and II 
and transforming growth factor [10,11]. Considering the 
broad range of effects of osteoporosis on the medical and 
health system, currently there is an increasing demand 
for alternative medications that can prevent and cure this 
silent ailment [12]. In this paper, we have reviewed the 
literature related to a selected medicinal herb, Quercus 
infectoria which may act specifically on osteoblastic pro-
liferation and differentiation. 
2. Quercus infectoria 
Quercus infectoria (QI) or manjakani is a small oak tree 
indigenous to Asia Minor and Persia. It is found in the 
Kumaun, Garhwal and Bijnor forests in India [13]. 
Although QI is not an indigenous to Malaysia, it is 
commonly utilized among the local Malay women as a 
herb especially for postpartum care [14]. QI or majuphal 
as it is known in India, is considered as one of the most 
powerful vegetable astringents in Indian medicine. It is 
used in the form of powder, decoction, infusion and 
ointment. Previous studies stated that QI had been used 
as a dental powder in the treatment of toothache and 
gingivitis [13,15,16]. However, the mechanism of the 
effects of QI on tooth and gingiva were not elucidated. 
The oak galls, used in commerce and medicine, are 
excrescences of the QI tree. It is formed as a result of the 
puncture of the bark of young twigs by the female 
gall-wasp, Cynips Gallae-tinctoriae, which lays its eggs 
inside. The young larva that hatches from the eggs feeds 
upon the tissues of the oak and secretes a peculiar fluid in 
its mouth. This fluid stimulates the cells of the tissues to 
rapidly divide resulting in abnormal development and the 
formation of a gall. The larva becomes completely 
enclosed in a nearly spherical mass, which projects from 
the twig, furnishing it with a supply of starch and other 
nutritive material. The growth of the gall continues as the 
egg or larva lives and reaches maturity. It then changes 
into a chrysalis, from which the fully develop gall-wasp 
will emerge and escape into the air through a hole bored 
with its mandibles at the side of the gall. For medicinal 
use, galls are collected before the insect escapes [13]. 
Elemental and physico-chemical analyses indicated the 
presence of important minerals in QI, such as calcium 
(Ca), magnesium (Mg), phosphorus (P), oxygen (O2), 
potassium (K), aluminium (AI), carbon (C), zinc (Zn), 
iron (Fe), manganese (Mn), nickel (Ni) and silica (Si) 
[17,18] (Table 1). Thus, QI may be a good source of 
minerals to treat a number of diseases that are mainly due 
to the deficiency of those minerals, for example osteopo- 
rosis which is a condition caused by Ca deficiency. 
Numerous studies have reported the essentiality of Ca 
and vitamin D for bone health [19-21]. Ca is one of the 
Table 1. Elemental composition of QI by using Atomic  
Absorption Spectrophotometer. 
No. Elements (ppm) Quercus infectoria (in 5% HCI) 
1 Calcium (Ca) 12700 
2 Phosphorus (P) 11100 
3 Potassium (K) 223633 
4 Magnesium (Mg) 20933 
5 Iron (Fe) 3587 
6 Manganese (Mn) 100 
7 Zinc (Zn) 329 
8 Nickel (Ni) 213 
Edited from Vermani et al. 2010 [18]. 
 
main bone-forming minerals and an appropriate supply to 
bone is essential at all stages of life. Studies in popula- 
tions with a low average intake of calcium suggest an 
increasing risk of hip fracture with declining calcium 
intake [22-24]. Both Ca and P are required for the ap- 
propriate mineralization of the skeleton and a depletion 
of serum phosphate leads to impaired bone mineraliza- 
tion and compromised osteoblast function [25]. In addi- 
tion to that, Mg is involved in bone and mineral homeo- 
stasis and is important in bone crystal growth and stabi- 
lization [26]. A significant correlation has been observed 
between serum Mg and bone metabolism. Gur et al. [27] 
demonstrated lower serum values of Mg in 70 osteo- 
porotic subjects compared to 30 non-osteoporotic post- 
menopausal women. Furthermore, Marangella et al. [28] 
had suggested that treatment with an alkaline salt, such 
as potassium citrate can reduce bone resorption levels in 
postmenopausal women with low bone density. Thus, the 
mineral constituents of QI may provide benefit to bone 
metabolism and prevent or even reverse osteoporosis. 
The QI gall extract is thought to have a variety of 
pharmacological properties including anti-diabetic [29], 
anti-tremor [30], local anesthetic, antiviral [31], anti- 
bacterial [32], anti-fungal [33], larvicidal [34], anti- 
microbial [35], anti-inflammation [36], wound healing 
[37] and many more. Umachigi et al. [38] found 
noticeable antioxidant activity in the QI gall extract, as 
the extract inhibited the superoxide and 1,1-diphenyl-2- 
picrylhydrazyl (DPPH) radical scavenging activities, and 
tyrosinase activities [39]. Flavonoid and phenolic com- 
pounds extracted from the QI galls are believed to have 
potential antioxidant activity and are often correlated 
with the antioxidant activity of phytomaterials. 
The QI galls possessed potent free radical quenching 
and potent antioxidant activity when tested both in 
chemical as well as biological models [40]. The main 
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constituents found in the QI galls are tannins (gallotannic 
acid) (50% - 70%), gallic acid (2% - 4%), ellagic acid, 
sugar and essential oils [41]. Other phytochemicals such 
as amentoflavone, hexamethyl ether, iso-cryptomerin and 
beta-sitosterol have also been isolated from QI [13]. 
Phytochemicals or phytonutrients are a large group of 
plant-derived chemical compounds and are divided into 
several classes: phenolics or polyphenols (flavonoids, 
phenolic acids, tannins, stilbenes, coumarins and lignans), 
carotenoids, alkaloids, sterols, terpenes and fibre. Phyto-
chemicals produced by plants are used to protect them-
selves, but recent research demonstrates that certain 
molecules may protect humans against some pathologies 
such as cancer, cardiovascular diseases and osteoporosis 
[42]. Polyphenols are aromatic compounds. Of all the 
aromatic compounds, flavonoids and tannins are most 
commonly found in plant organs [43]. As previously re- 
viewed by Habauzit & Horcajada [44], polyphenols can 
act on bone metabolism by modulating osteoblast prolife- 
ration, differentiation and mineralization, as well as os-
teoclast function [45]. 
3. The Osteoblast 
Osteoblasts involved in bone formation are derived from 
precursors originating in the bone marrow. These 
precursors are multipotent mesenchymal stem cells that 
can be differentiated into several kinds of tissue specific 
cells such as osteoblasts, myoblasts, adipocytes and 
chondrocytes [45]. Bone formation is a tightly regulated 
process which is characterized by a sequence of events 
starting with the commitment of osteoprogenitor cells, 
their differentiation into pre-osteoblasts and finally ma- 
ture osteoblasts whose function is to synthesize bone 
matrix that becomes progressively mineralized. Inherent- 
ly, based on observations in vivo and in bone nodule 
formation in vitro, the process is subdivided into three 
stages: 1) proliferation; 2) extracellular matrix develop- 
ment and maturation (differentiation); and 3) mineraliza- 
tion [46]. Each stage is regulated by the coordinated 
expression of major transcription factors [47]. 
The most important transcription factors controlling 
bone formations are RunX2, Osterix, β-catenin, activa- 
ting transcription factor-4, activator protein-1 (AP-1) and 
CCAAT/enhancer binding proteins (C/EBP). Other tran- 
scription factors belonging to homeobox proteins (Msx 
and D1x proteins) or to helix-loop-helix protein (Id and 
Twist) may play a role in osteoblast development [47]. 
Furthermore, the expression of all these transcription 
factors is known to be modulated by several hormones; 
parathyroid hormone (PTH), oestrogen, glucocorticoids, 
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], or growth 
factors; bone morphogenetic protein (BMP), transform- 
ing growth factor-β (TGF-β), insulin-like growth factor-1 
(IGF-1), fibroblast growth factor-2 (FGF-2) [48,49]. For 
example, PTH promotes bone formation in part through 
phosphorylation and activation of Runx2, resulting in 
activation of osteoblast genes [50]. Several research 
groups, using cell culture systems, have demonstrated 
that BMPs are potent local factors that regulate 
osteoblast differentiation [51-54]. 
Osteoblasts express various phenotypic markers such 
as alkaline phosphatase (ALP) collagen type 1, osteopon- 
tin (OPN), bone sialoprotein (BSP) and osteocalcin 
(OCN). Many markers are available and are currently 
used to study the influence of several factors on osteo- 
blast developmental stages or functions. Indeed, ALP, 
OPN and bone BSP are early markers of the osteoblast 
phenotype while OCN plays a role in mineralization [55]. 
In general, ALP increases and then decreases when 
mineralization is well progressed, OPN peaks twice 
during proliferation and then again later but prior to 
certain other matrix proteins, including BSP and OCN. 
BSP is expressed transiently very early and is then 
upregulated again in differentiated osteoblasts forming 
bone and OCN appears approximately concomitantly 
with mineralization [46]. 
Research also suggests that osteoblasts exert an influ- 
ence on osteoclasts by using receptors that can control 
the chemical or hormonal signals which would either 
initiate or inhibit osteoclastic action [56]. Osteoclasts are 
derive from haematopoietic progenitors (monocyte/ma- 
crophage lineage) in the bone marrow and are respon- 
sible for bone resorption. Osteoblasts can produce both 
RANK-L (the ligand for receptor activator of nuclear 
factor-kappa β, NF-κβ) and osteoprotegerin. Indeed, 
RANK-ligand binds to RANK on osteoclast precursors 
and stimulates osteoclast proliferation, whereas osteo- 
protegerin (a circulating binder of RANK-ligand), re- 
duces the amount of RANK-ligand and thus osteoclast 
activity [57]. These inherent qualities of the osteoblast 
aid the coupling of osteoblasts to osteoclasts which is 
vital in bone remodeling process [58,59]. 
Active osteoblasts are found on the surface of newly 
formed bone, where they synthesize the organic matrix 
and regulate mineralization. Once the osteoblast has 
completed bone formation it can undergo various trans- 
formations, either becoming a flattened bone lining cell, 
undergo programmed cell death (apoptosis), or it can 
become embedded within the newly formed bone tissue 
transforming into an osteocyte [60-62]. 
4. Effects of Polyphenols on Bone 
Metabolism 
To the best of our knowledge, the effect of QI gall 
extract on bone metabolism has never be reported. 
However, several studies have found that polyphenols 
can act on human cells. Studies on modulation of cell 
function by polyphenols had been performed in different 
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in vitro models such as cancer cells [63,64], epithelial 
cells [65,66] or skeletal cells, but little is known 
regarding osteoblastic cells. The only available data with 
respect to osteoblasts is from Bu et al. [67], who studied 
the influence of dried plum polyphenol extract on 
MC3T3-E1 on osteoblasts under normal and inflamma- 
tory conditions. This extract was found to be non toxic 
for osteoblasts, and was able to stimulate alkaline 
phosphatase (ALP) activity and mineralized nodule for- 
mation. They concluded that the dried plum polyphenols 
enhance osteoblast activity and function by up-regulating 
Runx2, Osterix and IGF-I and increasing lysyl oxidase 
expression, and at the same time attenuate osteoclasto- 
genesis signaling [67]. 
Moreover, a short-term clinical study with postmeno- 
pausal women demonstrated that dietary supplementation 
with 100 g of dried plums (a rich source of phenolic and 
flavonoid compounds) per day for 3 months positively 
influenced the bone formation markers, bone-specific 
alkaline phosphatase (BSAP) and IGF-1. Higher levels of 
both serum IGF-I and BSAP are associated with greater 
rates of bone formation by osteoblasts [68]. 
Gallotannins, which are parts of polyphenols, have 
been shown to regulate multiple biological activities 
including antioxidative and antitumor capacities. How- 
ever, their effects on bone metabolism remain to be 
elucidated [44]. The only study available had been 
carried out by Park et al. [69]. They found that furosin, 
an elagitannin has an inhibitory activity on the differen- 
tiation of both murine bone marrow mononuclear cells 
and Raw264.7 cells into mature osteoclasts. Park et al. 
[69] conclude that furosin could modulate osteoclastic 
function through mechanisms involving inhibition of 
RANKL-induced p38MAPK and JNK/AP-1 activation as 
well as by actin ring formation. 
Recently, Holzer et al. (2012) [70], showed that green 
tea extract (GTE) with high levels of polyphenols 
(mainly catechins) may influence bone mineral density 
(BMD) in smokers by reducing their oxidative stress 
levels and enhancing viability of osteoblasts, thus on 
doing so, supporting bone healing in general. They 
conclude that dietary supplementation with GTE appears 
to be an effective and simple way to counter high 
reactive oxygen species (ROS) level due to cigarette 
smoke. In addition to that, supplementation with green 
tea polyphenols (GTF) in female rats resulted in higher 
values of bone formation indicators [femoral bone 
mineral content (BMC), BMD and serum OCN], but 
lower the values of bone resoprtion indicators [serum 
tartrate-resistant acid phosphate (TRAP), urinary 8- 
hydroxy-2’-deoxyguanosine (8-OHdG) and cyclooxy- 
genase-2 (COX-2) levels] [71]. 
All of the previous findings indicate that polyphenols 
may give effects not only on osteoblasts but also on os-
teoclasts. Polyphenols can enhance osteoblast activity 
and mineralization by up-regulating Runx2, Osterix, 
IGF-I, BSAP, ALP, OCN, BMC, BMD as well as inhibit 
osteoclastogenesis via inhibition of RANKL expression, 
TRAP, 8-OHdG, COX-2 levels, and activation of 
JNK/AP-1. These combined effects of polyphenols on 
osteoblasts and osteoclasts are useful in maintaining the 
bone remodeling process which is the key endpoint in the 
management of osteoporosis [45]. 
5. Conclusion 
Osteoporosis is considered as a worldwide major public 
health problem. To overcome the wide range of side ef-
fects produced by the synthetic osteoporotic drugs, it is 
desirable to find a new naturally occuring anabolic agent 
or the so-called “green medicine” that can stimulate new 
bone formation, which is primarily a function of the os-
teoblasts. The QI gall extract contains high levels of im-
portant minerals (calcium, phosphorus, potassium and 
magnesium) and polyphenols which are important for 
long-term bone health and for the prevention of osteopo-
rosis. Although evidence of a link between polyphenols 
and osteoblasts is not sufficiently strong to give precise 
dietary recommendations, the related accumulating data 
suggests that QI may have a potential anabolic effect on 
bone metabolism. Therefore, laboratory studies need to 
be done to answer the question of whether QI can pro-
duce an effect on bone metabolism (especially on the 
osteoblasts) and eventually elucidate the exact mecha-
nism of the action of QI on bone which can lead to fun-
damental knowledge that may be used to derive a new 
source for the treatment of osteoporosis. 
6. Acknowledgements 
The authors were grateful to the Universiti Sains Malay-
sia for funding this work under USM short term grant 
number 304/PPSK/61312042. 
REFERENCES 
[1] L. G. Raisz, “Pathogenesis of Osteoporosis: Concepts, 
Conflicts, and Prospects,” Journal of Clinical Investiga- 
tion, Vol. 115, No. 12, 2005, pp. 3318-3325.  
doi:10.1172/JCI27071 
[2] M. P. Caulfield and R. E. Reitz, “Biochemical Markers of 
Bone Turnover and Their Utility in Osteoporosis,” Medi-
cal Laboratory Observer (MLO), Vol. 36, No. 4, 2004, pp. 
34-37. 
[3] “Fractures Neck of Femur,” Royale Collage of Physicians, 
London, 1989.  
[4] C. Cooper, G. Campion and L. J. Melton, “Hip Fractures 
in the Elderly: A World-Wide Projection,” Osteoporosis 
International, Vol. 2, No. 6, 1992, pp. 285-289.  
doi:10.1007/BF01623184 
Copyright © 2012 SciRes.                                                                              OJEMD 
H. HAPIDIN  ET  AL. 86 
[5] L. J. Melton, “Epidemiology of Fractures,” In: L. J. Mel-
ton, Ed., Osteoporosis: Etiology, Diagnosis, and Man-
agement, Lippincott-Raven, Philadelphia, 1995, pp. 225- 
247. 
[6] R. Eastell, I. T. Boyle, J. Compston, et al., “Management 
of Male Osteoporosis: Report of the UK Consensus 
Group,” Quarterly Journal of Medicine, Vol. 91, No. 2, 
1998, pp. 71-92. doi:10.1093/qjmed/91.2.71  
[7] O. Johnell and J. A. Kanis, “An Estimate of the World-
wide Prevalence and Disability Associated with Osteo-
porotic Fractures,” Osteoporosis International, Vol. 17, 
No. 12, 2006, pp. 1726-1733.  
doi:10.1007/s00198-006-0172-4 
[8] E. Lau, P. Suriyamongpaisal, J. Lee, et al., “Risk Factors 
for Hip Fracture in Asian Men and Women: The Asian 
Osteoporosis Study,” Journal of Bone and Mineral Re-
search, Vol. 16, No. 3, 2001, pp. 572-580.  
doi:10.1359/jbmr.2001.16.3.572 
[9] P. S. Lim, F. B. Ong, N. Adeeb, et al., “Bone Health in 
Urban Midlife Malaysian Women: Risk Factors and Pre-
vention,” Osteoporosis International, Vol. 16, No. 12, 
2005, pp. 2069-2079. doi:10.1007/s00198-005-2003-4 
[10] S. R. Joshi and D. V. Paramar, “Osteoporosis,” The In-
dian Practice, Vol. 50, 1997, pp. 254-268.  
[11] M. Wheeler, “Osteoporosis,” Medical Clinics of North 
America, Vol. 60, No. 6, 1976, pp. 1213-1224.  
[12] S. K. Mitra, M. V. Venkataranganna, S. Gopumadhava, et 
al., “The Beneficial Effect of OST-6 (OsteoCare, a Her- 
bomineral Formulation in Experimental Osteoporosis,” 
Phytomedicine, Vol. 8, No. 3, 2001, pp. 195-201.  
doi:10.1078/0944-7113-00034 
[13] C. P. Khare, “Quercus,” Indian Herbal Remedies: Ra-
tional Western Therapy, Ayurvedic and Other Traditional 
Usage, 2004, pp. 395-396. 
[14] Z. Muhammad and A. M. Mustafa, “Traditional Malay 
Medicine Plants,” Penerbit Fajar Bakti Sdn. Bhd, Kuala 
Lumpur, 1994. 
[15] A. V. S. Kottakkal, “Indian Medicinal Plants,” Orient 
Longman Ltd., Andhra Pradesh, 1995. 
[16] S. K. Bhattacharjee, “Handbook of Medicinal Plants,” 
Pointer Publishers, Jaipur, 2001. 
[17] L. K. Soon, E. Hasni, K. S. Law, et al., “Ultrastructural 
Findings and Elemental Analysis of Quercus Infectoria 
Oliv,” Annals of Microscopy, Vol. 7, 2007, pp. 32-37. 
[18] A. Vermani, Navneet, Prabhat and A. Chauhan, “Physico- 
Chemical Analysis of Ash of Some Medicinal Plants 
Growing in Uttarakhand, India,” Nature and Science, Vol. 
8, No. 6, 2010, pp. 88-91. 
[19] S. A. New, “Bone Health: The Role of Micronutrients,” 
British Medical Bulletin, Vol. 55, No. 3, 1999, pp. 619- 
633. doi:10.1258/0007142991902501 
[20] J. Z. Ilich and J. E. Kerstetter, “Nutrition in Bone Health 
Revisited: A Story Beyond Calcium,” Journal of the 
American Collage of Nutrition, Vol. 19, No. 6, 2000, pp. 
715-737.  
[21] R. P. Heaney, “Bone Health,” The American Journal of 
Clinical Nutrition, Vol. 85, 2007, pp. 300S-303S. 
[22] E. Lau, S. Donnan, D. J. Barker and C. Cooper, “Physical 
Activity and Calcium Intake in Fracture of the Proximal 
Femur in Hong Kong,” British Medical Journal, Vol. 297, 
No. 6661, 1988, pp. 1441-1443.  
doi:10.1136/bmj.297.6661.1441 
[23] O. Johnell, B. Gullberg, J. A. Kanis, et al., “Risk Factors 
for Hip Fracture in European Women: The MEDOS 
Study,” Journal of Bone and Mineral Research, Vol. 10, 
No. 11, 1995, pp. 1802-1815.  
doi:10.1002/jbmr.5650101125 
[24] J. Kanis, O. Johnell, B. Gullaberg, et al., “Risk Factors of 
Hip Fracture in Men from Southern Europe: The MEDOS 
Study. Mediterranean Osteoporosis Study,” Osteoporosis 
International, Vol. 9, No. 1, 1999, pp. 45-54.  
doi:10.1007/s001980050115 
[25] “American Society for Bone and Mineral Research,” In: 
M. Favus, Ed., Primer of the Metabolic Bone Diseases 
and Disorders of Mineral Metabolism, Lippincott Wil-
liams & Wilkins, Philadelphia, 1999, pp. 257-284. 
[26] A. Prentice, “Diet, Nutrition and the Prevention of Os-
teoporosis,” Public Health Nutrition, Vol. 7, No. 1A, 
2004, pp. 227-243. doi:10.1079/PHN2003590 
[27] A. Gur, L. Colpan, K. Nas, R. Cevik, et al., “The Role of 
Trace Minerals in the Pathogenesis of Postmenopausal 
Osteoporosis and a New Effect of Calcitonin,” Journal of 
Bone and Mineral Metabolism, Vol. 20, No. 1, 2002, pp. 
39-43. doi:10.1007/s774-002-8445-y 
[28] M. Marangella, M. D. Stefano, S. Casalis, S. Berutti, et 
al., “Effects of Potassium Citrate Supplementation on 
Bone Metabolism,” Calcified Tissue International, Vol. 
74, No. 4, 2004, pp. 330-335.  
doi:10.1007/s00223-003-0091-8 
[29] J. K. Hwang, T. W. Kong, N. I. Baek and Y. R. Pyun, 
“α-Glycosidase Inhibitory Activity of Hexagalloyl Glu- 
cose from the Galls of Quercus Infectoria,” Planta 
Medica, Vol. 66, No. 3, 2000, pp. 273-274.  
doi:10.1055/s-2000-8569 
[30] M. S. Dar, M. Ikram and T. Fakouhi, “Pharmacology of 
Quercus infectoria oliv,” Journal of Pharmaceutical Sci-
ences, Vol. 46, No. 6, 1976, pp. 1791-1794.  
doi:10.1002/jps.2600651224 
[31] G. Hussein, H. Miyashiro, N. Nakamura, M. Hattori, et 
al., “Inhibitory Effects of Sudanese Medicinal Plant Ex- 
tracts on Hepatitis C Virus Protease,” Phytotherapy Re- 
search, Vol. 14, No. 7, 2000, pp. 510-516.  
doi:10.1002/1099-1573(200011)14:7<510::AID-PTR646
>3.0.CO;2-B 
[32] S. Fatima, A. H. A. Farooqi, R. Kumar, T. R. S. Kumar 
TRS and S. P. S. Khanuja, “Antibacterial Activity Pos-
sessed by Medicinal Plants Used in Tooth Powders,” 
Journal of Medicinal and Aromatic Plant Sciences, Vol. 
22, No. 4a, 2001, pp. 187-189. 
[33] M. Digraki, M. H. Alma, A. Ilcim and S. Sen, “Antibac- 
terial and Antifungal Effects of Various Commercial 
Plant Extracts,” Pharmaceutical Biology, Vol. 37, No. 3, 
1999, pp. 216-220. doi:10.1076/phbi.37.3.216.6307 
[34] A. Redwane, H. B. Lazrek, S. Bouallam, M. Markouk, et 
al., “Larvicidal Activity of Extracts from Quercus lusita- 
nia var. infectoria Galls (Oliv.),” Journal of Ethnophar- 
Copyright © 2012 SciRes.                                                                              OJEMD 
H. HAPIDIN  ET  AL. 87
macology, Vol. 79, No. 2, 2002, pp. 261-263.  
doi:10.1016/S0378-8741(01)00390-7 
[35] S. Voravuthikunchai, A. Lortheeanuwat, W. Jeeju, T. 
Sririrak, et al., “Effective Medicinal Plants against En-
terohaemorrhagic Escherichia coli O 157:H7,” Journal of 
Ethnopharmacology, Vol. 94, No. 1, 2004, pp. 49-50.  
doi:10.1016/j.jep.2004.03.036 
[36] G. Kaur, H. Hamidi, A. Ali, M. S. Alam and M. Athar, 
“Anti-Inflammatory Evaluation of Alcoholic Extract of 
Galls of Quercus infectoria,” Journal Ethnopharmacol-
ogy, Vol. 90, No. 2-3, 2004, pp. 285-292.  
doi:10.1016/j.jep.2003.10.009 
[37] S. P. Umachigi, K. N. Jayaveera, C. K. Ashok Kumar, et 
al., “Studied on Wound Healing Properties of Quercus 
infectoria,” Tropical Journal of Pharmaceutical Research, 
Vol. 7, No. 1, 2008a, pp. 913-919.  
[38] S. P. Umachigi, K. N. Jayaveera, C. K. Ashok Kumar and 
G. S. Kumar, “Antioxidant Potential of Galls of Quercus 
infectoria,” The Internet Journal of Pharmacology, Vol. 5, 
No. 2, 2008b.  
[39] S. Rohana, S. Vimala, A. Abdul Rashih and A. Mohd 
IIham, “Skin Whitening and Antioxidant Properties of 
Quercus Infectoria Galls,” Proceedings of the Seminar on 
Medicinal Plant, Forest Research Institute Malaysia 
(FRIM), Selangor, 20-21 July 2004, pp. 188-191. 
[40] G. Kaur, M. Athar and M. S. Alam, “Quercus infectoria 
Galls Possess Antioxidant Activity and Abrogates Oxida-
tive Stress-Induced Functional Alterations in Murine 
Macrophages,” Chemico-Biological Interactions, Vol. 
171, No. 3, 2008, pp. 272-282.  
doi:10.1016/j.cbi.2007.10.002 
[41] J. Bruneton, “Pharmacognosy: Phyochemistry, Medicinal 
Plants,” 2nd Edition, Lavoisier Pub., Hampshire, 1999. 
[42] A. Scalbert, C. Manach, C. Morand, et al., “Dietary 
Polyphenols and the Prevention of Diseases,” Critical 
Review in Food Science and Nutrition, Vol. 45, No. 4, 
2005, pp. 287-306. doi:10.1080/1040869059096  
[43] Z. Luthar, “Polyphenol Classification and Tannin Content 
of Buckwheat Seeds (Fagopyrum esculentum Moench),” 
Fagopyrum, Vol. 12, 1992, pp. 36-42. 
[44] V. Habauzit and M. N. Horcajada, “Phenolic Phyto-
chemicals and Bone,” Phytochemistry Reviews, Vol. 7, 
No. 2, 2008, pp. 313-344. 
[45] A. Trzeciakiewicz, V. Habauzit and M. N. Hocajada, 
“When Nutrition Interacts with Osteoblast Function: Mo-
lecular Mechanisms of Polyphenols,” Nutrition Research 
Reviews, Vol. 22, No. 1, 2009, pp. 68-81.  
doi:10.1017/S095442240926402X 
[46] J. E. Aubin, “Mesenchymal stem cells and osteoblast 
differentiation,” In: J. P. Bilezikian, L. G. Raisz and T. J. 
Martin, Eds., Principals of Bone Biology, Academic Press, 
San Diego, 2008, pp. 85-107.  
doi:10.1016/B978-0-12-373884-4.00026-4 
[47] P. J. Marie, “Transcription Factors Controlling Os-
teoblastogenesis,” Archives of Biochemistry and Bio-
physics, Vol. 473, No. 2, 2008, pp. 98-105.  
doi:10.1016/j.abb.2008.02.030   
[48] G. J. Strewler, “Local and Systemic Control of the Os-
teoblast,” Journal of Clinical Investigation, Vol. 107, No. 
3, 2001, pp. 271-272. doi:10.1172/JCI11777 
[49] D. J. Baylink, R. D. Finkelman and S. Mohan, “Growth 
Factors to Stimulate Bone Formation,” Journal of Bone 
and Mineral Research, Vol. 8, No. S2, 1993, pp. S565- 
S572. doi:10.1002/jbmr.5650081326 
[50] V. Krishnan, T. L. Moore, Y. L. Ma, L. M. Helvering, et 
al., “Parathyroid Hormone Bone Anabolic Action Re-
quires Cbfa1/Runx2-Dependent Signaling,” Molecular 
Endocrinology, Vol. 17, No. 3, 2003, pp. 423-435.  
doi:10.1210/me.2002-0225 
[51] T. Katagiri, Yamaguchi, A. Ikeda, T. Yoshiki, et al., “The 
Non-Osteogenic Mouse Pluripotent Cell Line, C3H10T1/2, Is 
Induced to Differentiate into Osteoblastic Cells by Re-
combinant Human Bone Morphogenetic Protein-2,” Bio-
chemical and Biophysical Research Communications, 
Vol. 172, No. 1, 1990, pp. 295-299.  
doi:10.1016/S0006-291X(05)80208-6 
[52] A. Yamaguchi, T. Katagiri, T. Ikeda, J. M. Wozney, et al., 
“Recombinant Human Bone Morphogenetic Protein-2 
Stimulates Osteoblastic Maturation and Inhibits and In-
hibits Myogenic Differentiation in vitro,” The Journal of 
Cell Biology, Vol. 113, No. 3, 1991, pp. 681-687.  
doi:10.1083/jcb.113.3.681 
[53] T. K. Sampath, J. C. Maliakal, P. V. Hauschka, W. K. 
Jones, et al., “Recombinant Human Osteogenic Protein-1 
(hOP-1) Induces New Bone Formation in vitro with a 
Specific Activity Comparable with Natural Bovine Os-
teogenic Protein and Stimulates Osteoblast Proliferation 
and Differentiation in vitro,” The Journal of Biological 
Chemistry, Vol. 267, No. 28, 1992, pp. 20352-20362.  
[54] S. E. Gitelman, M. Kirk, E. H. Filvaroff, A. J. Kahn, et al., 
“Vgr-1/BMP-6 Induces Osteoblastic Differentiation of 
Pluripotential Mesenchymal Cells,” Cell Growth and Dif-
ferentiation, Vol. 6, No. 7, 1995, pp. 827-836.  
[55] G. S. Stein and J. B. Lian, “Molecular Mechanisms Me-
diating Proliferation Differentiation Interrelationships 
during Progressive Developmental of the Osteoblast Phe-
notype,” Endocrine Reviews, Vol. 14, No. 4, 1993, pp. 
424-442. 
[56] S. Marks and P. Odgren, “Structure and developmental of 
the skeleton,” In: J. P. Bilezikian, L. G. Raisz and G. A. 
Rodan, Eds., Principles of Bone Biology, Academic Press, 
San Diego, 2002, pp. 3-15. 
[57] L. C. Hofbauer and A. E. Heufelder, “Role of Receptor 
Activator of Nuclear Factor Kappa-B Ligand and Osteo-
protegerin in Bone Cell Biology,” Journal of Molecular 
Medicine, Vol. 79, No. 5-6, 2001, pp. 243-253.  
doi:10.1007/s001090100226 
[58] J. Lian, G. Stein, E. Canalis, P. Gehron Robey and A. 
Boskey, “Bone formation: Osteoblast lineage cells, 
growth factors, matrix proteins and the mineralization 
process,” In: M. Favus, Ed., Primer on Metabolic Dis-
eases and Disorders of Mineral Metabolism, Lippincott 
William & Wilkins, Philadelphia, 1999, pp. 14-29.  
[59] A. M. Parfitt, “The Mechanism of Coupling: A Role for 
the Vasculature,” Bone, Vol. 26, No. 4, 2000, pp. 319-323. 
doi:10.1016/S8756-3282(00)80937-0 
[60] A. M. Parfitt, “Osteonal and Hemi-Osteonal Remodeling: 
Copyright © 2012 SciRes.                                                                              OJEMD 
H. HAPIDIN  ET  AL. 
Copyright © 2012 SciRes.                                                                              OJEMD 
88 
The Spatial and Temporal Framework for Signal Traffic 
in Adult Human Bone,” Journal of Cellular Biochemistry, 
Vol. 55, No. 3, 1994, pp. 273-286.  
doi:10.1002/jcb.240550303 
[61] R. Baron, “Anatomy and Ultrastructural of Bone,” In: M. 
Favus, Ed., Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism, Lippincott William & 
Wilkins, Philadelphia, 1999, pp. 3-10.  
[62] D. Sommerfeldt and C. Rubin, “Biology of Bone and 
How It Orchestrates the Form and Function of the Skele-
ton,” European Spine Journal, Vol. 10, No. S2, 2001, pp. 
S86-S95. doi:10.1007/s005860100283 
[63] V. Noe, S. Penuelas, R. M. Lamuela-Raventos, et al., 
“Epicatechin and a Cocoa Polyphenolic Extract Modulate 
Gene Expression in Human Caco-2 Cells,” Journal of 
Nutrition, Vol. 134, No. 10, 2004, pp. 2509-2516. 
[64] C. H. Ko, S. C. Shen, H. Y. Lin, et al., “Flavanones 
Structure-Related Inhibition on TPA-Induced Tumor 
Promotion through Suppression of Extracellular Sig-
nal-Regulated Protein Kinases: Involvement of Pros-
taglandin E-2 in Anti-Promotive Process,” Journal of 
Cellular Physiology, Vol. 193, No. 1, 2002, pp. 93-102. 
doi:10.1002/jcp.10154 
[65] J. O’Prey, J. Brown, J. Fleming, et al., “Effects of Dietary 
Flavonoids on Major Signal Transduction Pathways in 
Human Epithelial Cells,” Biochemical Pharmacology, 
Vol. 66, No. 11, 2003, pp. 2075-2088.  
doi:10.1016/j.bcp.2003.07.007 
[66] R. Vittal, Z. E. Selvanayagam, Y. Sun, et al., “Gene Ex- 
pression Changes Induced by Green Tea Polyphenol (2)- 
Epigallocatechin-3-Gallate in Human Bronchial Epithelial 
21BES Cells Analyzed by DNA Microarray,” Molecular 
Cancer Therapeutics, Vol. 3, No. 9, 2004, pp. 1091-1099. 
[67] S. Y. Bu, T. S. Hunt and B. J. Smith, “Dried Plum Poly-
phenols Attenuate the Detrimental Effects of TNF-a on 
Osteoblast Function Coincident with Up-Regulation of 
Runx2, Osterix and IGF-I,” The Journal of Nutritional 
Biochemistry, Vol. 20, No. 1, 2009, pp. 35-44.  
doi:10.1016/j.jnutbio.2007.11.012 
[68] B. H. Arjmandi, D. A. Khalil, E. A. Lucas, et al., “Dried 
Plumps Improve Indices of Bone Formation in Post-
menopausal Women,” Journal of Women’s Health Gen-
der-Based Medicine, Vol. 11, No. 1, 2002, pp. 61-68. 
doi:10.1089/152460902753473471 
[69] E. K. Park, M. S. Kim, S. H. Lee, et al., “Furosin, an 
Ellagitannin, Suppresses RANKL-Induced Osteoclast 
Differentiation and Function through Inhibition of MAP 
Kinase Activation and Actin Ring Formation,” Bio-
chemical and Biophysical Research Communications, 
Vol. 325, No. 4, 2004, pp. 1472-1480.  
doi:10.1016/j.bbrc.2004.10.197 
[70] N. Holzer, K. F. Braun, S. Ehnert, J. T. Egana, T. L. 
Schenck, A. Buchholz, et al., “Green Tea Protects Human 
Osteoblasts from Cigarette Smoke-Induced Injury: Possi-
ble Clinical Application,” Langenbecks Archives of Sur-
gery, Vol. 397, No. 3, 2012, pp. 467-474.  
doi:10.1007/s00423-011-0882-8 
[71] C. L. Shen, J. K. Yeh, J. J. Cao, O. L. Tatum, et al., 
“Green Tea Polyphenols Mitigate Bone Loss of Female 
Rats in a Chronic Inflammation-Induced Bone Loss 
Model,” Journal of Nutritional Biochemistry, Vol. 21, No. 
10, 2010, pp. 968-974. doi:10.1016/j.jnutbio.2009.08.002 
 
